Multiple Myeloma
Conditions
Keywords
Multiple Myeloma, BCMA CAR T-cell therapy, HCT, Memorial Sloan Kettering Cancer Center, 23-166
Brief summary
This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.
Interventions
OTHERLecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM
Physician investigators will review a lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM that discusses current information in regards to available cellular therapies in RRMM and a proposed treatment algorithm.
BEHAVIORALHospital Anxiety and Depression Scale
Depression and anxiety will be assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item self-rated questionnaire
BEHAVIORALDuke-UNC Functional Social Support Questionnaire
A 14-item, self-administered, multidimensional, functional social support questionnaire has been reduced to an 11 items to a brief and easy-to-complete two-scale, eight-item functional social support instrument.
BEHAVIORALDistress Thermometer
The Distress Thermometer is a single-item visual analog scale used to screen cancer patients for the presence of psychological distress
BEHAVIORALFACT-BMT
The FACT-BMT Version 4.0 is a 37 item self-report questionnaire that measures the effect of cancer on Quality of Life domains
BEHAVIORALPsychosocial Assessments of Candidates for Transplantation
The PACT scale is a single page 10-item rating scale with high inter-rater reliability that has been used extensively in solid organ transplantation
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Patient * Diagnosis of Multiple Myeloma after January 1, 2017. * Karnofsky Performance Status \> 70% * ≥ 2 lines of prior therapy * Anticipated to start new a line of therapy for RRMM within the next 12 months * Age 18-80 years of age. * English or Spanish speaking. * Willing to provide informed consent * Willing to perform study procedures. Physician Investigator * Be a Co-Investigator * Agree to comply with study procedures
Exclusion criteria
Patient * Active CNS disease * Patients who already have a definitive plan are to be excluded
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rates of referral | Up to 76 months | To prospectively estimate the rates of referral and utilization of salvage autologous hematopoietic cell transplantation (HCT) and B cell maturation antigen (BCMA) Targeted Chimeric Antigen Receptor (CAR) autologous T cell therapies among patients with RRMM. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORHeather Landau, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed